Jasmine L Jacobs-Wingo1, Cheyenne C Jim2, Amy V Groom3. 1. Office for State, Tribal, Local, and Territorial Support, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: wvi2@cdc.gov. 2. IHRC, Inc., Atlanta, Georgia; Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 3. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Division of Epidemiology and Disease Prevention, Indian Health Service, Rockville, Maryland.
Abstract
INTRODUCTION: Although Indian Health Service, tribally-operated, and urban Indian (I/T/U) healthcare facilities have higher human papillomavirus (HPV) vaccine series initiation and completion rates among adolescent patients aged 13-17 years than the general U.S. population, challenges remain. I/T/U facilities have lower coverage for HPV vaccine first dose compared with coverage for other adolescent vaccines, and HPV vaccine series completion rates are lower than initiation rates. Researchers aimed to assist I/T/U facilities in identifying interventions to increase HPV vaccination series initiation and completion rates. STUDY DESIGN: Best practice and intervention I/T/U healthcare facilities were identified based on baseline adolescent HPV vaccine coverage data. Healthcare professionals were interviewed about barriers and facilitators to HPV vaccination. Researchers used responses and evidence-based practices to identify and assist facilities in implementing interventions to increase adolescent HPV vaccine series initiation and completion. Coverage and interview data were collected from June 2013 to June 2015; data were analyzed in 2015. SETTING/PARTICIPANTS: I/T/U healthcare facilities located within five Indian Health Service regions. INTERVENTION: Interventions included analyzing and providing feedback on facility vaccine coverage data, educating providers about HPV vaccine, expanding access to HPV vaccine, and establishing or expanding reminder recall and education efforts. MAIN OUTCOME MEASURES: Impact of evidence-based strategies and best practices to support HPV vaccination. RESULTS: Mean baseline first dose coverage with HPV vaccine at best practice facilities was 78% compared with 46% at intervention facilities. Mean third dose coverage was 48% at best practice facilities versus 19% at intervention facilities. Intervention facilities implemented multiple low-cost, evidence-based strategies and best practices to increase vaccine coverage. At baseline, most facilities used electronic provider reminders, had standing orders in place for administering HPV vaccine, and administered tetanus, diphtheria, and acellular pertussis and HPV vaccines during the same visit. At intervention sites, mean coverage for HPV initiation and completion increased by 24% and 22%, respectively. CONCLUSIONS: A tailored multifaceted approach addressing vaccine delivery processes and patient and provider education may increase HPV vaccine coverage. Published by Elsevier Inc.
INTRODUCTION: Although Indian Health Service, tribally-operated, and urban Indian (I/T/U) healthcare facilities have higher human papillomavirus (HPV) vaccine series initiation and completion rates among adolescent patients aged 13-17 years than the general U.S. population, challenges remain. I/T/U facilities have lower coverage for HPV vaccine first dose compared with coverage for other adolescent vaccines, and HPV vaccine series completion rates are lower than initiation rates. Researchers aimed to assist I/T/U facilities in identifying interventions to increase HPV vaccination series initiation and completion rates. STUDY DESIGN: Best practice and intervention I/T/U healthcare facilities were identified based on baseline adolescent HPV vaccine coverage data. Healthcare professionals were interviewed about barriers and facilitators to HPV vaccination. Researchers used responses and evidence-based practices to identify and assist facilities in implementing interventions to increase adolescent HPV vaccine series initiation and completion. Coverage and interview data were collected from June 2013 to June 2015; data were analyzed in 2015. SETTING/PARTICIPANTS: I/T/U healthcare facilities located within five Indian Health Service regions. INTERVENTION: Interventions included analyzing and providing feedback on facility vaccine coverage data, educating providers about HPV vaccine, expanding access to HPV vaccine, and establishing or expanding reminder recall and education efforts. MAIN OUTCOME MEASURES: Impact of evidence-based strategies and best practices to support HPV vaccination. RESULTS: Mean baseline first dose coverage with HPV vaccine at best practice facilities was 78% compared with 46% at intervention facilities. Mean third dose coverage was 48% at best practice facilities versus 19% at intervention facilities. Intervention facilities implemented multiple low-cost, evidence-based strategies and best practices to increase vaccine coverage. At baseline, most facilities used electronic provider reminders, had standing orders in place for administering HPV vaccine, and administered tetanus, diphtheria, and acellular pertussis and HPV vaccines during the same visit. At intervention sites, mean coverage for HPV initiation and completion increased by 24% and 22%, respectively. CONCLUSIONS: A tailored multifaceted approach addressing vaccine delivery processes and patient and provider education may increase HPV vaccine coverage. Published by Elsevier Inc.
Authors: P A Briss; L E Rodewald; A R Hinman; A M Shefer; R A Strikas; R R Bernier; V G Carande-Kulis; H R Yusuf; S M Ndiaye; S M Williams Journal: Am J Prev Med Date: 2000-01 Impact factor: 5.043
Authors: Cheyenne C Jim; Jennifer Wai-Yin Lee; Amy V Groom; David K Espey; Mona Saraiya; Steve Holve; Ann Bullock; Jean Howe; Judith Thierry Journal: J Womens Health (Larchmt) Date: 2012-02-06 Impact factor: 2.681
Authors: Matthew F Daley; Lori A Crane; Lauri E Markowitz; Sandra R Black; Brenda L Beaty; Jennifer Barrow; Christine Babbel; Sami L Gottlieb; Nicole Liddon; Shannon Stokley; L Miriam Dickinson; Allison Kempe Journal: Pediatrics Date: 2010-08-02 Impact factor: 7.124
Authors: Carolyn B Bridges; Laura P Hurley; Walter W Williams; Aparna Ramakrishnan; Anna K Dean; Amy V Groom Journal: Am J Prev Med Date: 2015-09-14 Impact factor: 5.043
Authors: Peter G Szilagyi; Stanley Schaffer; Richard Barth; Laura P Shone; Sharon G Humiston; Sandra Ambrose; Francisco Averhoff Journal: Arch Pediatr Adolesc Med Date: 2006-02
Authors: Delf C Schmidt-Grimminger; Maria C Bell; Clemma J Muller; Diane M Maher; Subhash C Chauhan; Dedra S Buchwald Journal: BMC Infect Dis Date: 2011-09-24 Impact factor: 3.090
Authors: Emiko Petrosky; Joseph A Bocchini; Susan Hariri; Harrell Chesson; C Robinette Curtis; Mona Saraiya; Elizabeth R Unger; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2015-03-27 Impact factor: 17.586
Authors: Laurie D Elam-Evans; David Yankey; Jenny Jeyarajah; James A Singleton; Robinette C Curtis; Jessica MacNeil; Susan Hariri Journal: MMWR Morb Mortal Wkly Rep Date: 2014-07-25 Impact factor: 17.586
Authors: Sameer V Gopalani; Ami E Sedani; Amanda E Janitz; Shari C Clifton; Jennifer D Peck; Ashley Comiford; Janis E Campbell Journal: J Community Health Date: 2022-02-24
Authors: Nadja Albertsen; Anna Rask Lynge; Nils Skovgaard; Jesper Søndergaard Olesen; Michael Lynge Pedersen Journal: Int J Circumpolar Health Date: 2020-12 Impact factor: 1.228
Authors: Jacqueline M Hirth; Kayla A Eboreime; Leslie E Cofie; Richard E Rupp; Abbey B Berenson Journal: Hum Vaccin Immunother Date: 2022-02-18 Impact factor: 3.452
Authors: Anna Acampora; Adriano Grossi; Andrea Barbara; Vittoria Colamesta; Francesco Andrea Causio; Giovanna Elisa Calabrò; Stefania Boccia; Chiara de Waure Journal: Int J Environ Res Public Health Date: 2020-10-30 Impact factor: 3.390